Dimethyl Fumarate

富马酸二甲酯

Report date: 2026/05/20 20:02:01
NMEFirst In Class

Base Information

Drug NameDimethyl Fumarate
Drug Alias Name二甲基延胡索酸Delayed-release dimethyl fumarate二甲基富马酸Gastro-resistant dimethyl fumarateGastro-resistant DMF +[19] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNuclear factor erythroid 2-related factor 2 stimulants
TargetsNuclear factor erythroid 2-related factor 2
Therapy Area/IndicationsPlaque psoriasisOverweightObesity +[15] 
Global Approved IndicationsMultiple Sclerosis
Approved Indications in ChinaMultiple Sclerosis
Original Approved Country/TerritoryUnited States
Original Approved Date2013/03/27
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[51] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBiogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesMedical University Of LodzBiogen Netherlands BvBiogen Inc +[6] 
Inactive CompaniesIqvia Rds (Shanghai) Co LtdInstitut D'Investigació Biomèdica De BellvitgeUniversity Of Michigan +[7] 
Active IndicationsPlaque psoriasisPsoriasisDiabetic Nephropathies +[6] 
Inactive IndicationsOverweightObesityScleroderma, Systemic +[9] 

Other Information

ATC CodeL04AX07
Related LinksWikipediaDrugBankKEGG